Clinical trial
Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer
NCT00020748 · Georgetown University, Other · Completed
Key facts
| NCT number | NCT00020748 |
|---|---|
| Title | Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer |
| Official title | A Phase I Study of Epirubicin in Combination With Irinotecan in Patients With Advanced Cancer |
| Lead sponsor | Georgetown University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | epirubicin hydrochloride, irinotecan hydrochloride |
| Start date | Aug 1, 2000 |
| Primary completion | Oct 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 24, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: